期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

免疫毒素ScFv(anti HER2)-PE38的复性与纯化 被引量：1

Renaturation and Purification of Immunotoxin ScFv (anti HER2)-PE38
原文传递
导出
摘要 目的建立免疫毒素ScFv(anti HER2)-PE38的分离纯化工艺。方法免疫毒素ScFv(anti HER2)-PE38变性后,进行金属螯合柱层析复性和纯化,再用分子筛层析进行精纯,SDS-PAGE分析纯化产物。结果包涵体形式存在的免疫毒素ScFv(anti HER2)-PE38以8 mol/L尿素溶解效果较好;当复性梯度为稀释液从0到100%,共用时150 min,流速为2 ml/min时,复性效果较好,复性后的目的蛋白纯度可达95%以上;以凝胶柱Superdex 200进行分子筛层析效果较好,纯化产物的纯度可达98%以上。结论已建立了免疫毒素ScFv(anti HER2)-PE38的分离纯化工艺,为进一步的研究奠定了基础。 Objective To develop a procedure for purification of immunotoxin ScFv（anti HER2）-PE38.Methods Immunotoxin ScFv（anti HER2）-PE38 was de-naturalized,then re-naturalized and purified by metal chelate column chromatography,and further purified by molecular sieve chromatography.The purified product was analyzed by SDS-PAGE.Results The immunotoxin ScFv（anti HER2）-PE38 in a form of inclusion body was effectively dissolved with 8 mol / L urea.The optimal gradient of diluent,time and flow rate for renaturation were 0 ～ 100%,150 min and 2 ml / min respectively.The purity of target protein after renaturation reached more than 95%.The molecular sieve chromatography with Superdex 200 showed satisfactory effect,by which the purity of purified product reached more than 98%.Conclusion A procedure for purification of immunotoxin ScFv（anti HER2）-PE38 was developed,which laid a foundation of further study.
作者 王国华 程云章
机构地区 上海中信国健药业有限公司 上海理工大学医疗器械与食品学院
出处 《中国生物制品学杂志》 CAS CSCD 2011年第2期221-224,共4页 Chinese Journal of Biologicals
关键词 免疫毒素类 单链抗体 分离纯化 Immunotoxin Single chain antibody Purification
分类号 R392-33 [医药卫生—免疫学]
  • 相关文献

参考文献12

  • 1Potala S, Verma RS. Modified DT-IL2 fusion toxin targeting uniquely IL2Ralpha expressing leukemia cell lines-construction and characterization [J]. J Biotechnol, 2010, 148 (2-3): 147-155.
  • 2Kreitman RJ. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies [J]. BioDrugs, 2009, 23 (1): 1-13.
  • 3Hansen JK, Weldon JE, Xiang L, et al. A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in mice [J]. J Immunother, 2010, 33 (3): 297-304.
  • 4Mussai F, Campana D, Bhojwani D, et al. Cytotoxicity of the anti- CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia [J]. Br J Haematol, 2010, 150 (3): 352- 358.
  • 5Kuroda K, Liu H, Kim S, et al. Saporin toxin-conjugated monoclonal antibody targeting prostate-specific membrane antigen has potent anticancer activity [ J ]. Prostate, 2010, 70 (12) : 1286-1294.
  • 6Onda M, Wang QC, Guo HF, et al. In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9 (Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma [J]. Cancer Res, 2004, 64 (4): 1419-1424.
  • 7Okamura H, Nagata K, Komatsu T, et al. A novel costimulatory factor for gamma interferon induction found in the livers of mice causes endotoxic shock [J]. Infect Immun, 1995, 63 (10): 3966-3972.
  • 8Wels W, Biburger M, Muller T, et al. Recombinant immunotoxins and retargeted killer cells: employing engineered antibody fragments for tumor-specific targeting of cytotoxic effectors [J]. Cancer Immunol Immunother, 2004, 53 (3) : 217-226.
  • 9Pincus SH, Marcotte TK, Forsyth BM, et al. In vivo testing of anti-HIV immunotoxins [J]. Methods Mol Biol, 2001, 166: 277- 294.
  • 10Hu CC, Ji HM, Chen SL, et al. Investigation of a plasmid containing a novel immunotoxin VEGF165-PE38 gene for antiangiogenic therapy in a malignant glioma model [J]. Int J Cancer, 2010, 127 (9): 2222-2229.

同被引文献12

  • 1Kiethaber T, Rudolph R, Kohler HH, et al. Protein aggregation in vitro and in vivo : A quantitative model of the kinetic competition between folding and aggregation. Bio Technology, 1991, 9 ( 9 ) : 825-829.
  • 2Rudolph R, Lilie H. In vitro folding of inclusion body proteins. FASEBJ, 1996, 10 ( 1 ) : 49-56.
  • 3Fan XD, Xu DS, Lu B, et al. Improving the refolding of NTA protein by urea gradient and arginine gradient size-exclusion chromatography. J Biochem Biophys Methods, 2008, 70 ( 6 ) : 1130-1138.
  • 4Gu ZY, Su ZG, Janson JC. Urea gradient size-exclusion chromatog- raphy enhanced the yield of lysozyme refolding. J Chromatogr A, 2001,918 (2) : 311-318.
  • 5Nakashima Y, Yasuda T, Takeshita H, et al. Molecular, biochemical and immunological studies of hen pancreatic deoxyribonuclease I. Inter J Biochem & CeUBiol, 1999, 31 : 1315-1326.
  • 6Sbak S, Capon DJ, Hellmiss R. Recombinant human DNasc I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA, 1990, 87 ( 23 ) : 9188-9192.
  • 7Kishi K, Yasuda T, Takeshita H. DNase I: structure, function, and use in medicine and forensic science. Legal Med, 2001, 3 ( 2 ) : 69-83.
  • 8Bradford MM, Mcrorie RA, Williams WL. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem, 1976, 72 ( 1-2 ) : 248-254.
  • 9Nadane D, Yasuda T, Kishi K. Measurement of deoxyribonuclease I activity in human tissues and body fluids by single radial enzyme- diffusion method. Clinical Chemistry, 1993, 39 ( 3 ) : 448-452.
  • 10Fujihara J, Takatsuka H, Kataoka K, et al. Two deoxyribonuclease I gene polymorphisms and correlation between genotype and its activity in Japanese population. Legal Medicine, 2007, 9 ( 5 ) : 233-236.

引证文献1

中国生物制品学杂志
2011年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部